Home › Companies › Janux Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Janux Therapeutics, Inc.’s Form 8-K, filed 2026-06-12 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Proxy season: 2024-2025 2025-2026
Explore Janux Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Janux Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-12 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Natasha Hernday | 42,850,103 | -- | -- | 4,519,796 | 6,375,023 | Majority: yes |
| Elect Director: Eric Dobmeier | 46,279,387 | -- | -- | 1,090,512 | 6,375,023 | Majority: yes |
| Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered | 53,560,969 | 113,446 | 70,507 | -- | -- | Majority: yes |
| Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in the Proxy Statement | 42,749,182 | 4,574,376 | 46,341 | -- | 6,375,023 | Majority: yes |
Source: Janux Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-12 — read the filing on EDGAR.
Each item below shows how the 214 asset managers that disclosed a Janux Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 6 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Janux Therapeutics, Inc.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in the Proxy Statement”): 42,749,182 for, 4,574,376 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,865,458 outstanding shares: 70% for, 8% against (78% of the company cast a for/against vote).
The 213 asset managers below cast 91% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 11,189,693 | 0 | 0 | 0 | For |
| Janus Henderson | 7,810,838 | 0 | 0 | 0 | For |
| Fidelity | 4,954,597 | 0 | 0 | 0 | For |
| BlackRock | 4,456,732 | 21,328 | 0 | 0 | For |
| Vanguard | 3,449,919 | 6,545 | 0 | 0 | For |
| State Street | 2,395,619 | 11,916 | 0 | 0 | For |
| Prosight Management, LP | 1,349,472 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,160,241 | 0 | 0 | 0 | For |
| Logos Global Management LP | 0 | 1,000,000 | 0 | 0 | Against |
| ORBIMED ADVISORS LLC | 983,600 | 0 | 0 | 0 | For |
| Wellington | 0 | 973,505 | 0 | 0 | Against |
| Irenic Capital Management LP | 765,804 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 744,422 | 0 | 0 | Against |
| Charles Schwab | 709,707 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 688,187 | 0 | 0 | 0 | For |
| Nantahala Capital Management, LLC | 579,169 | 0 | 0 | 0 | For |
| Alyeska Investment Group, L.P. | 0 | 465,296 | 0 | 0 | Against |
| Point72 | 436,095 | 0 | 0 | 0 | For |
| Deep Track Capital, LP | 419,248 | 0 | 0 | 0 | For |
| Rock Springs Capital Management LP | 367,009 | 0 | 0 | 0 | For |
| Woodline Partners LP | 345,402 | 0 | 0 | 0 | For |
| Allspring | 287,888 | 0 | 0 | 0 | For |
| Northern Trust | 247,838 | 4,931 | 0 | 0 | For |
| ADAR1 Capital Management, LLC | 174,014 | 0 | 0 | 0 | For |
| Citadel | 153,783 | 0 | 0 | 0 | For |
Showing the 25 largest of 213 asset managers. See all 213 in the interactive database.
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Janux Therapeutics, Inc.’s own tally for this item (“Elect Director: Eric Dobmeier”): 46,279,387 for, 1,090,512 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,865,458 outstanding shares: 76% for, 2% withheld (78% of the company cast a for/withheld vote).
The 56 asset managers below cast 100% of the shares they voted on this item FOR (11,531,316 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,084,586 | 0 | 3 | 0 | For |
| Fidelity | 2,441,000 | 0 | 0 | 0 | For |
| BlackRock | 2,032,682 | 0 | 0 | 0 | For |
| State Street | 1,558,734 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 688,187 | 0 | 0 | 0 | For |
| Charles Schwab | 354,755 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 0 | 295,009 | 0 | Abstain |
| Bridge Builder Trust | 15,852 | 0 | 130,078 | 0 | Abstain |
| Allspring | 124,330 | 0 | 0 | 0 | For |
| Hartford | 112,004 | 0 | 0 | 0 | For |
| Northwestern Mutual | 102,751 | 0 | 0 | 0 | For |
| TIAA | 94,823 | 0 | 0 | 0 | For |
| Equitable | 59,954 | 0 | 24,880 | 0 | For |
| Delaware/Macquarie | 76,601 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 73,409 | 0 | 0 | 0 | For |
| Putnam | 68,488 | 0 | 0 | 0 | For |
| Lincoln Financial | 65,106 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 62,209 | 0 | Abstain |
| JPMorgan | 60,586 | 0 | 0 | 0 | For |
| Tema ETF Trust | 52,188 | 0 | 0 | 0 | For |
| Jackson National | 41,374 | 0 | 2,277 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 41,999 | 0 | 0 | 0 | For |
| ProShares | 41,678 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 39,284 | 0 | 0 | 0 | For |
| Pacific Life | 36,058 | 0 | 0 | 0 | For |
Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.
Combines 4 wordings of this item as funds reported it.
90% Majority: yes · of votes cast
Janux Therapeutics, Inc.’s own tally for this item (“Elect Director: Natasha Hernday”): 42,850,103 for, 4,519,796 withheld, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,865,458 outstanding shares: 70% for, 7% withheld (78% of the company cast a for/withheld vote).
The 56 asset managers below cast 100% of the shares they voted on this item FOR (11,475,835 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,084,581 | 0 | 8 | 0 | For |
| Fidelity | 2,441,000 | 0 | 0 | 0 | For |
| BlackRock | 2,032,682 | 0 | 0 | 0 | For |
| State Street | 1,556,876 | 0 | 1,858 | 0 | For |
| JANUS INVESTMENT FUND | 688,187 | 0 | 0 | 0 | For |
| Charles Schwab | 354,755 | 0 | 0 | 0 | For |
| Federated Hermes | 295,009 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 145,930 | 0 | 0 | 0 | For |
| Allspring | 0 | 0 | 124,330 | 0 | Abstain |
| Hartford | 112,004 | 0 | 0 | 0 | For |
| Northwestern Mutual | 102,751 | 0 | 0 | 0 | For |
| TIAA | 94,823 | 0 | 0 | 0 | For |
| Equitable | 59,954 | 0 | 24,880 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 76,601 | 0 | Abstain |
| QUANTITATIVE MASTER SERIES LLC | 73,409 | 0 | 0 | 0 | For |
| Putnam | 68,488 | 0 | 0 | 0 | For |
| Lincoln Financial | 38,953 | 0 | 26,153 | 0 | For |
| Dimensional | 0 | 0 | 62,209 | 0 | Abstain |
| JPMorgan | 60,586 | 0 | 0 | 0 | For |
| Tema ETF Trust | 52,188 | 0 | 0 | 0 | For |
| Jackson National | 41,374 | 0 | 2,277 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 41,999 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 41,678 | 0 | Abstain |
| Guardian Variable Products Trust | 2,300 | 0 | 36,984 | 0 | Abstain |
| Pacific Life | 36,058 | 0 | 0 | 0 | For |
Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.
Combines 2 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Janux Therapeutics, Inc.’s own tally for this item (“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP”): 53,560,969 for, 113,446 against, per its Form 8-K filed 2026-06-12 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 60,865,458 outstanding shares: 88% for, 0.2% against (88% of the company cast a for/against vote).
The 56 asset managers below cast 100% of the shares they voted on this item FOR (12,047,026 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 3,084,589 | 0 | 0 | 0 | For |
| Fidelity | 2,441,000 | 0 | 0 | 0 | For |
| BlackRock | 2,032,682 | 0 | 0 | 0 | For |
| State Street | 1,558,734 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 688,187 | 0 | 0 | 0 | For |
| Charles Schwab | 354,755 | 0 | 0 | 0 | For |
| Federated Hermes | 295,009 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 145,930 | 0 | 0 | 0 | For |
| Allspring | 124,330 | 0 | 0 | 0 | For |
| Hartford | 112,004 | 0 | 0 | 0 | For |
| Northwestern Mutual | 102,751 | 0 | 0 | 0 | For |
| TIAA | 94,823 | 0 | 0 | 0 | For |
| Equitable | 84,834 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 76,601 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 73,409 | 0 | 0 | 0 | For |
| Putnam | 68,488 | 0 | 0 | 0 | For |
| Lincoln Financial | 65,106 | 0 | 0 | 0 | For |
| Dimensional | 62,209 | 0 | 0 | 0 | For |
| JPMorgan | 60,586 | 0 | 0 | 0 | For |
| Tema ETF Trust | 52,188 | 0 | 0 | 0 | For |
| Jackson National | 43,651 | 0 | 0 | 0 | For |
| MASTER INVESTMENT PORTFOLIO | 41,999 | 0 | 0 | 0 | For |
| ProShares | 41,678 | 0 | 0 | 0 | For |
| Guardian Variable Products Trust | 39,284 | 0 | 0 | 0 | For |
| Pacific Life | 36,058 | 0 | 0 | 0 | For |
Showing the 25 largest of 56 asset managers. See all 56 in the interactive database.
Ranked by the number of Janux Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 60,865,458 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 18.38% |
| 2 | Janus Henderson | 12.83% |
| 3 | Fidelity | 8.14% |
| 4 | BlackRock | 7.36% |
| 5 | Vanguard | 5.68% |
| 6 | State Street | 3.96% |
| 7 | Prosight Management, LP | 2.22% |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1.91% |
| 9 | Logos Global Management LP | 1.64% |
| 10 | ORBIMED ADVISORS LLC | 1.62% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| Entities affiliated with RA Capital Healthcare Fund, L.P. | 20.37% | DEF14A |
| BlackRock | 8.93% | 13F |
| Entities affiliated with Janus Henderson Group plc | 8.79% | DEF14A |
| JANUS HENDERSON GROUP PLC | 6.89% | 13G |
| FMR LLC | 5.77% | DEF14A |
| Entities affiliated with Prosight | 5.19% | DEF14A |
| Prosight Management, LP | 5.18% | 13G |
| David Campbell, Ph.D. | 5.03% | DEF14A |
| Vanguard Group | 4.78% | 13F |
| FMR (Fidelity) | 4.17% | 13F |
Percentages above are of 60,865,458 shares outstanding, as reported by Janux Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Janux Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At Janux Therapeutics, Inc.'s shareholder meeting held 2026-06-11, in the 2025-2026 proxy season, 214 asset managers reported how they voted on 4 ballot items in their SEC Form N-PX filings, covering 1,005 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS, AS… — FOR was 90% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Janux Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-12.
Janux Therapeutics, Inc. proxy season coverage: 2024-2025 · 2025-2026 (this page).